Evidence map›Paper›PMID 41117202›Full record

ArticleTransfusion2025

In vitro and in vivo evaluation of leukoreduced red blood cells after automated separation of whole blood.

Rebecca L Sedjo, Gina K Aga, Elissa J Flaumenhaft, Moritz Stolla, Larry J Dumont, Susanne Marschner, Laurie Sutor, Frances Compton, Shawnagay Nestheide, Neeta Rugg and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Rebecca L SedjoClinical Affairs, Terumo Blood and Cell Technologies, Lakewood, Colorado, USA.
Gina K AgaScientific Affairs, Terumo Blood and Cell Technologies, Lakewood, Colorado, USA.
Elissa J FlaumenhaftScientific Affairs, Terumo Blood and Cell Technologies, Lakewood, Colorado, USA.
Moritz StollaBloodworks Northwest Research Institute, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-2866-1674
Larry J DumontVitalant Research Institute, Denver, Colorado, USA.ORCID https://orcid.org/0000-0002-1715-0748
Susanne MarschnerVitalant Research Institute, Denver, Colorado, USA.
Laurie SutorCarter BloodCare, Bedford, Texas, USA.
Frances ComptonCarter BloodCare, Bedford, Texas, USA.ORCID https://orcid.org/0000-0001-6523-7699
Shawnagay NestheideHoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio, USA.
Neeta RuggHoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio, USA.
Phillip LópezClinical Affairs, Terumo Blood and Cell Technologies, Lakewood, Colorado, USA.
Marley ShippsClinical Affairs, Terumo Blood and Cell Technologies, Lakewood, Colorado, USA.
Nero EveroClinical Affairs, Terumo Blood and Cell Technologies, Lakewood, Colorado, USA.
S Lawrence BaileyBloodworks Northwest Research Institute, Seattle, Washington, USA.
Daire ByrneBloodworks Northwest Research Institute, Seattle, Washington, USA.
Christina GloorScientific Affairs, Terumo Blood and Cell Technologies, Lakewood, Colorado, USA.
Caroline LeiteVitalant Research Institute, Denver, Colorado, USA.
Jose A CancelasHoxworth Blood Center, University of Cincinnati, Cincinnati, Ohio, USA.
Alice J ChenScientific Affairs, Terumo Blood and Cell Technologies, Lakewood, Colorado, USA.

Funding

Novel Strategies to Improve Blood Transfusion PracticeP01HL158688 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Hongbo R Luo · 2022 to 2026
$12.9M
Mitochondria mediated intercellular metabolic coupling in bone marrow regenerationR01DK124115 · NIDDK · DANA-FARBER CANCER INST · PI Jose A. Cancelas · 2020 to 2026
$1.9M
NHLBI NIH HHS P01 HL158688NIDDK NIH HHS R01 DK124115Terumo BCT
6 · The paper itself

Abstract

backgroundLeukoreduced red blood cells (LR-RBCs) prepared from whole blood (WB) with the Reveos™ Automated Blood Processing System (Reveos System) are required to meet US Food and Drug Administration (FDA) criteria for RBC component in vitro quality and in vivo 24-h RBC recovery after 42-day storage. STUDY DESIGN AND

methodsFor the in vitro study, 65 Reveos-derived LR-RBC units were stored for 42 days in citrate phosphate dextrose (CPD)/Additive Solution Formula 5 (AS-5). Units were evaluated for post-filtration residual white blood cell (rWBC) content, post-filtration RBC recovery, and percent hemolysis at end of storage. In vivo 24-h recovery of 42-day stored autologous Reveos-derived LR-RBCs was determined in 26 healthy participants with standard single (

resultsFor all evaluable units processed in the in vitro study, post-filtration rWBC content was <5 × 10

conclusionThe Reveos System met FDA's criteria for RBC component in vitro quality and in vivo 24-h recovery after 42-day storage.

Indexed as

Blood PreservationErythrocytesLeukocyte Reduction ProceduresAdultFemaleHemolysisHumansMaleMiddle Agedautomated blood component processinghemolysisleukoreduced RBCred blood cell in vivo recoveryReveos

Identifiers

PMID41117202
PMCPMC12752190

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.